Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM10 | O14672 | 20/20 | 0.60 |
| ▸ | MMP2 | P08253 | 18/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.60 |
| ▸ | MMP9 | P14780 | 14/20 | 0.50 |
| ▸ | MMP3 | P08254 | 7/20 | 0.49 |
| ▸ | MMP12 | P39900 | 2/20 | 0.49 |
| ▸ | MMP14 | P50281 | 2/20 | 0.49 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.49 |
| ▸ | ADAM33 | Q9BZ11 | 2/20 | 0.49 |
| ▸ | ADAM8 | P78325 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 4/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4530938 | 1.00 | ADAM10 (0.60) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL5038314 | 0.91 | ADAM10 (0.52) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL5039536 | 0.91 | ADAM10 (0.52) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL6022178 | 0.90 | ADAM10 (0.51) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL4536939 | 0.90 | ADAM10 (0.51) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL6022479 | 0.89 | ADAM10 (0.54) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL5044826 | 0.89 | ADAM10 (0.54) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL5045222 | 0.89 | ADAM10 (0.63) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL17743482 | 0.88 | ADAM10 (0.49) | ADAM10MMP2ERBB2MMP9MMP3 | |
| SCHEMBL5035094 | 0.88 | ADAM10 (0.49) | ADAM10MMP2ERBB2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622569-A4 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | INCYTE CORP (US) | 2008-08-27 | — | — | EP | claimed |
| EP-1622569-A2 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES | Incyte Corporation (US) | 2006-02-08 | — | — | EP | claimed |
| WO-2004096139-A2 | AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLOPROTEASES | INCYTE CORPORATION (US) | 2004-11-11 | — | — | WO | claimed |
| EP-2637679-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | The University of Chicago (US) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012064865-A1 | ROLE OF ADAM10 AND ITS RELEVANCE TO DISEASE AND THERAPEUTICS | THE UNIVERSITY OF CHICAGO (US) | 2012-05-18 | — | — | WO | disclosed |
| EP-1962863-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | Conforma Therapeutics Corporation (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007075572-A2 | ORALLY ACTIVE PURINE-BASED INHIBITORS OF HEAT SHOCK PROTEIN 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129334-A1 | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 | HSP90AB1, HSP90AA1, HSP90AB2P | ADAM10 4682/4885MMP2 3754/4885ERBB2 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.